Fig. 2-c. Third
bone density scan (Achilles Ultrasonometer) of subject 2 (female,
age 57 years) nine months after second scan, and 11 months after
last taking OsteoPhase during evaluation phase. Results indicated
a continued increase in BMD between 2nd and 3rd scan, from 75%
to 77% (yellow highlighted area), indicating continuing and sustained
benefits from the formula.
The
content provided by this site is for informational purposes only and
has
not been approved by the U.S. FDA. This site is not intended to provide
personal medical advice, which should be obtained from a medical professional.
